SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong Q3 results and raised full-year outlook are being overshadowed by a sharp selloff, with traders citing negative cash flow amid heavy capacity investment, a stretched valuation, and broader pressure on AI-linked stocks. Bulls view the results and data-center power demand as evidence of strong growth, while bears question cash generation and whether expectations had become too high.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digitals strong quarterly results, higher guidance, and dividend increase are drawing attention, but shares have sold off despite the positive report. Traders are debating whether the decline reflects broader weakness in AI and storage stocks and fears of peak-cycle margins, or an overreaction to results that supporters say show continued demand.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas shares plunged after Phase 3 data for its personalized melanoma vaccine with Mercks Keytruda surfaced ahead of the planned presentation; although the combination reduced recurrence-or-death risk, traders widely viewed the results as falling short of lofty expectations after the stocks sharp run-up. The debate centers on whether the selloff is an overreaction to positive clinical results or a reassessment of the vaccines commercial promise and Modernas valuation.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor and tech selloff, amid AI/data-center financing concerns and geopolitical risk, has been magnified by SOXLs 3x leverage. Traders are split between viewing the plunge as an oversold buying opportunity and warning that semiconductor and AI valuations could fall further.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples resilience near record highs, including on weak tech-market sessions, is driving attention, with traders pointing to defensive rotation and reports of strong iPhone Duo demand ahead of earnings. Bulls see durable demand and a potential breakout, while skeptics question the valuation and attribute the strength to positioning or market flows rather than improving fundamentals.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs sharp drop reflects a tech and semiconductor selloff as concerns resurfaced about AI investment returns and financing, alongside higher oil prices and geopolitical risk. Traders are divided between expecting a deeper correction and viewing the pullback as a buying opportunity near support.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

Semiconductors are selling off sharply alongside the Nasdaq, with traders citing concerns about AI investment financing and credit availability, as well as broader oil and geopolitical pressures. The community is split between calling the decline an oversold buying opportunity and warning that AI-bubble fears could drive further losses.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers latest quarterly results and outlook are driving attention: earnings and margins beat expectations, but revenue fell short and the company cut its full-year sales guidance as HOKA and UGG growth slowed, weighing on the shares. Traders are divided between viewing the selloff as excessive given profitability and buybacks, and seeing the lower outlook as evidence of weakening growth.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is drawing attention amid a sharp selloff in memory and semiconductor stocks, with traders citing broader AI-capex worries and concerns that strong storage earnings may not sustain peak-cycle expectations. The community is split between buyers treating the drop as a correction ahead of earnings and bears pointing to broken technical support and competition risks.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgents CFO departure triggered a sharp selloff, followed by company clarification that he was not leaving over a disagreement and a preliminary update that first-quarter revenue and adjusted EBITDA would exceed prior guidance. Traders are divided between viewing the drop as an overreaction given the companys backlog and growth outlook, and worrying that the abrupt transition signals undisclosed financial issues.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Earnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to Decline

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for...

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

BioMarin Appoints Cara Bauer as Chief People Officer

BioMarin Appoints Cara Bauer as Chief People Officer BioMarin Appoints Cara Bauer as Chief People OfficerPR NewswireSAN RAFAEL, Calif., Oct. 5, 2026Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology IndustriesAppointment Effective Oct. 5...

BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual Congress

BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual Congress BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual CongressPR...

FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug

AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of DirectorsPR NewswireSAN RAFAEL, Calif., Sept...

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Biomarin Pharmaceutical Inc. - Registered Shares

RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout 

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Martin Shkreli called RARE stock “very cheap” and said BioMarin and other rare-disease drugmakers should explore acquiring Ultragenyx.</li><li>RARE stock's selloff followed the failure of Apazunersen in a Phase 3 Angelman syndrome trial, where the drug missed both its primary and secondary endpoints.</li><li>Analysts said the investment case now depends on commercial execution, margin expansion, and upcoming pipeline catalysts.</li></ul><p>Shares of Ultragenyx Pharmaceutical (RARE) suffered their worst trading day on record and closed at an all-time low on Thursday after its Angelman syndrome treatment failed a key trial, prompting sweeping Wall Street target cuts and takeover speculation from former pharma executive Martin Shkreli.</p><p><a href="https://stocktwits.com/symbol/RARE">RARE stock</a> plunged about 44% to $14.85 on Thursday, wiping out nearly half its value in one session.</p><h2 class="st-heading-2"><strong>Shkreli Floats BioMarin Buyout&nbsp;</strong></h2><p>“$RARE is very cheap,” Shkreli&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2095490113857851515">said on X</a>. He argued that BioMarin Pharmaceutical (BMRN) and other rare-disease companies “should explore buying the company.” Shkreli, widely known as “Pharma Bro,” also claimed that the setback was foreseeable, saying “everyone and their brother with three months of med school/Shkreli training knew this trial would fail.”</p><p>BioMarin and Ultragenyx both develop and commercialize treatments for genetically defined rare diseases, with overlap in metabolic disorders, enzyme-replacement therapies, gene therapy and the specialist physicians they serve.&nbsp;</p><p>Ultragenyx shares crashed after its Phase 3 Aspire trial of Apazunersen, formerly GTX-102, failed both its primary and secondary endpoints. Patients receiving the drug showed no meaningful improvement over the control group in cognition or across a broader measure of Angelman symptoms.&nbsp;</p><p>Apazunersen was designed to activate a normally silent copy of the UBE3A gene. Angelman syndrome is a rare genetic brain disorder that can cause cognitive and movement impairments, seizures, balance problems and severe speech limitations. Ultragenyx estimates it affects about 60,000 people in accessible markets, with no approved treatment for its underlying cause.&nbsp;</p><p>The drug’s safety profile remained consistent with its Phase 1/2 program, but Ultragenyx said it will now assess the program’s future and implement “significant expense reductions.”&nbsp; The company said it will refocus on its expanding commercial portfolio, including recently approved Genglycos for glycogen storage disease type Ia, the potential approval of UX111 for Sanfilippo syndrome and geographic expansion of existing products.&nbsp;</p><h2 class="st-heading-2"><strong>Wall Street Slashes RARE Targets&nbsp;</strong></h2><p>Wall Street stripped the Angelman program from valuation models after the failure. RBC said the lack of numerical disclosure and limited positive framing suggested the drug may have produced no efficacy signal, while cautioning against automatically applying that conclusion to Ionis Pharmaceuticals’ (IONS) competing program due to differences in the molecules and dosing.</p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col><col><col><col></colgroup><tbody><tr><td>Firm</td><td>Rating Action</td><td>New Target</td><td>Previous Target</td><td>Target Cut</td><td>Upside From Current Levels</td></tr><tr><td>Jefferies</td><td>Maintained 'Buy'</td><td>$28</td><td>$77</td><td>64%</td><td>89%</td></tr><tr><td>TD Cowen</td><td>Maintained 'Buy'</td><td>$18</td><td>$49</td><td>63%</td><td>21%</td></tr><tr><td>Cantor Fitzgerald</td><td>Maintained 'Overweight'</td><td>$33</td><td>$103</td><td>68%</td><td>122%</td></tr><tr><td>Wedbush</td><td>Maintained 'Neutral'</td><td>$23</td><td>$30</td><td>23%</td><td>55%</td></tr><tr><td>RBC Capital</td><td>Cut to 'Sector Perform' from 'Outperform'</td><td>$19</td><td>$40</td><td>53%</td><td>28%</td></tr><tr><td>Canaccord</td><td>Maintained 'Buy'</td><td>$37</td><td>$83</td><td>55%</td><td>149%</td></tr><tr><td>BofA</td><td>Cut to 'Neutral' from 'Buy'</td><td>$20</td><td>$48</td><td>58%</td><td>35%</td></tr><tr><td>Morgan Stanley</td><td>Cut to 'Equal Weight' from 'Overweight'</td><td>$18</td><td>$74</td><td>76%</td><td>21%</td></tr></tbody></table></figure></div><p>TD Cowen called the failure unfortunate but not surprising given already-low expectations. Meanwhile, Jefferies said the outcome was surprising but added that Ultragenyx’s commercial franchise and broader potential was intact. Cantor Fitzgerald said it understood the trial’s risks but had hoped for better results.</p><p>Wedbush removed Apazunersen from its estimates and revised its spending assumptions. Morgan Stanley said the investment debate will now shift toward commercial execution, margin expansion and the remaining pipeline, warning that a strategic reset will take time.&nbsp;</p><h2 class="st-heading-2"><strong>How Do Retail Traders Feel About RARE?</strong></h2><p>On Stocktwits, retail sentiment for RARE jumped to ‘extremely bullish’ from ‘neutral’ levels a week ago amid a 9,200% surge in message volumes over the past week. The ticker’s watcher base has also jumped nearly 40% in a month and 27% in a week.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/rare_ss_4720fba7ea.png" alt="rare ss.png" width="643" height="346"><figcaption>RARE sentiment and message volume as of September 4 | Source: Stocktwits</figcaption></figure><p>One user&nbsp;<a href="https://stocktwits.com/LQQKER_INSIDER/message/663566322">said</a>, “all things considered, the call options appear cheap and I'd say the most prudent way to play this if you want to protect yourselves should it experience another big leg down instead. I'll give this a speculative BUY rating.”</p><p><stembedurl>https://stocktwits.com/LQQKER_INSIDER/message/663566322</stembedurl></p><p>Another user said, “$RARE overreacting. They still generating $740 revenue and have 5 commercialized drugs and q drug to be launched in Q4 and 1 drug has a PDUFA on 9/19/2026. Also, institutional ownership is 128%. This will open &gt;$22|</p><p><stembedurl>https://stocktwits.com/SeniorVip/message/663510523</stembedurl></p><p>RARE stock has declined 53% over the past year.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-nvidia-hugging-face-no-brainer-wall-street-threat-openai-anthropic/cZswMddRJwJ">Michael Burry Calls Nvidia-Hugging Face Deal A ‘No-Brainer’ — Wall Street Sees New Threat For OpenAI And Anthropic&nbsp;</a></p>

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76% and issuing multiple downgrades.

RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout

Ionis Pharmaceuticals Inc

Ultragenyx Pharmaceutical Inc

SPDR S&P Biotech ETF

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Current Price	$56.63
Prev Close	$55.21
Open	$55.40
Dividend Yield	0.00%
50-Day Moving Average	$62.24
Beta	0.65
Avg. Volume	2M
PE Ratio	148.85

52-Week High	$70.98
52-Week Low	$49.26
Market Capitalization	$10.69B
EPS (Annual)	$1.80
Price to Book	1.69
Revenue Per Employee	$1.01M

Feed

News

Sentiment

Earnings

Fundamentals

Info

BMRN Fundamentals